❌

Normal view

ForestPrune: High-ratio Visual Token Compression for Video Multimodal Large Language Models via Spatial-Temporal Forest Modeling

arXiv:2603.22911v1 Announce Type: cross Abstract: Due to the great saving of computation and memory overhead, token compression has become a research hot-spot for MLLMs and achieved remarkable progress in image-language tasks. However, for the video, existing methods still fall short of high-ratio token compression. We attribute this shortcoming to the insufficient modeling of temporal and continual video content, and propose a novel and training-free token pruning method for video MLLMs, termed ForestPrune, which achieves effective and high-ratio pruning via Spatial-temporal Forest Modeling. In practice, ForestPrune construct token forests across video frames based on the semantic, spatial and temporal constraints, making an overall comprehension of videos. Afterwards, ForestPrune evaluates the importance of token trees and nodes based on tree depth and node roles, thereby obtaining a globally optimal pruning decision. To validate ForestPrune, we apply it to two representative video MLLMs, namely LLaVA-Video and LLaVA-OneVision, and conduct extensive experiments on a bunch of video benchmarks. The experimental results not only show the great effectiveness for video MLLMs, e.g., retaining 95.8% average accuracy while reducing 90% tokens for LLaVA-OneVision, but also show its superior performance and efficiency than the compared token compression methods, e.g., +10.1% accuracy on MLVU and -81.4% pruning time than FrameFusion on LLaVA-Video.

Deciphering lung adenocarcinoma heterogeneity: a multi-omics approach reveals nuclear division fibroblasts as prognosticators and therapeutic targets

J Transl Med. 2026 Mar 20. doi: 10.1186/s12967-026-08022-3. Online ahead of print.

ABSTRACT

BACKGROUND: Lung adenocarcinoma (LUAD) is a predominant contributor to cancer‑related mortality globally. Lung‑associated fibroblasts (LAFs) are intricately linked to tumorigenesis and the tumor microenvironment (TME), but their heterogeneity and prognostic relevance in LUAD remain incompletely understood. This study aimed to systematically characterize LAF subsets across the spectrum of pulmonary disease, identify LAF subpopulations associated with LUAD prognosis, and construct a robust LAF‑based prognostic signature.

METHODS: We employed a multi-omics approach, leveraging bulk RNA data of 2719 patients from 19 LUAD cohorts, single-cell RNA (scRNA) sequencing data of 368,904 cells from 93 samples, and spatial transcriptomics data of 15,673 spots from 6 samples to characterize the landscape of LAFs across various stages of pulmonary disease. We employed multiple advanced machine learning algorithms to construct and validate a robust nuclear division LAFs (nLAFs) risk score (nLRS) prediction model.

RESULTS: We observed a dynamic and gradual increase in the proportion of LAFs during the progression of LUAD. Throughout this process, we identified nine LAFs subtypes and found nLAFs are significantly associated with the prognosis of LUAD. Utilizing 100 machine learning algorithm combinations and integrating nLAFs marker genes, we developed a five gene based nLRS model, which demonstrated superior performance than other 49 published models in predicting clinical outcomes for LUAD. Additionally, we observed distinct biological functions and immune cell infiltration in the TME between high and low nLRS groups. Exploratory analysis of pan-cancer immunotherapy cohorts suggested that patients with high nLRS scores may exhibit resistance to immunotherapy in some cancer types, but prospective validation in LUAD-specific cohorts is required. Conversely, high nLRS patients displayed increased sensitivity to chemotherapeutic and targeted therapies in preclinical models.

CONCLUSION: Our study introduces a candidate five-gene signature derived from nLAFs that may serve as a robust prognostic biomarker pending prospective validation, offering insights into personalized therapeutic strategies for LUAD patients.

PMID:41862916 | DOI:10.1186/s12967-026-08022-3

❌